Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar
Name:
imt-2019-0125.pdf
Size:
2.132Mb
Format:
PDF
Description:
Full text, Open Access article
Affiliation
Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitatsklinikum Heidelberg, Translational Lung Research Center, Heidelberg, GermanyIssue Date
2019
Metadata
Show full item recordCitation
Thomas M, Thatcher N, Goldschmidt J, Ohe Y, McBride HJ, Hanes V. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar. Immunotherapy. 2019;11(15):1337-51.Journal
ImmunotherapyDOI
10.2217/imt-2019-0125PubMed ID
31556762Additional Links
https://dx.doi.org/10.2217/imt-2019-0125Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.2217/imt-2019-0125
Scopus Count
Collections
Related articles
- Bevacizumab biosimilars: scientific justification for extrapolation of indications.
- Authors: Melosky B, Reardon DA, Nixon AB, Subramanian J, Bair AH, Jacobs I
- Issue date: 2018 Oct
- Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
- Authors: Kolberg HC, Colleoni M, Santi P, Demetriou GS, Segui-Palmer MA, Fujiwara Y, Hurvitz SA, Hanes V
- Issue date: 2019 Dec
- A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
- Authors: Markus R, McBride HJ, Ramchandani M, Chow V, Liu J, Mytych D, Fanjiang G
- Issue date: 2019 Aug
- SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation.
- Authors: Peeters M, Lipp HP, Park M, Yoon YC, Arnold D
- Issue date: 2023 Feb
- A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar.
- Authors: Cobb P, Niederwieser D, Cohen S, Hamm C, Burmester G, Seo N, Lehto SG, Hanes V
- Issue date: 2022 Jun